Why Centessa Stock Soared Today

MrDecoder · 2026-04-01T01:54:43+00:00

Centessa Pharmaceuticals' shares soared after Eli Lilly agreed to acquire the company for up to $7.8 billion, offering $38 per share plus potential future payouts. This deal, driven by Centessa's innovative drug candidates targeting severe sleep disorders, aims to close in Q3 pending approvals.

MrDecoder

2026-04-01 01:54:43

Abstract generation in progress

Shares of** Centessa Pharmaceuticals **(CNTA +44.02%) surged on Tuesday after the drugmaker struck a deal to be acquired by Eli Lilly (LLY +3.55%) for as much as $7.8 billion.

Image source: Getty Images.

An enticing offer for Centessa’s investors

Under the terms of the deal, Lilly would purchase Centessa for $38 per share in cash. That’s a premium of nearly 38% to the healthcare stock’s closing price on Monday.

Centessa’s shareholders would also receive a non-transferrable contingent value right, which could be valued at up to $9 per share if the pharmaceutical company’s investigational drugs achieve certain regulatory milestones.

The transaction is projected to close in the third quarter, subject to shareholder and regulatory approval.

Expand

NASDAQ: CNTA

Centessa Pharmaceuticals Plc

Today’s Change

(44.02%) $12.14

Current Price

$39.72

Key Data Points

Market Cap

$3.7B

Day’s Range

$39.57 - $40.26

52wk Range

$9.60 - $40.26

Volume

48M

Avg Vol

1.4M

Gross Margin

93.96%

Advancing neuroscience

Centessa is developing a novel class of drugs, known as orexin receptor 2 (OX2R) agonists, to treat daytime sleepiness and other neurological conditions. Its most promising experimental drug, cleminorexton, showed best-in-class potential in Phase 2 clinical studies for severe sleep disorders, including narcolepsy and idiopathic hypersomnia.

“Orexin receptor biology represents one of the most compelling mechanistic opportunities in neuroscience as a direct intervention on the master switch of the sleep-wake cycle,” Lilly executive Carole Ho said. “Centessa has assembled a portfolio with the breadth and depth to improve wakefulness across a broad array of indications.”

Blockbuster potential

Lilly is wisely using the windfall from its highly successful GLP-1 drugs Mounjaro and Zepbound to diversify its development pipeline. Centessa’s experimental therapies could become top sellers in a potential $20 billion market for treatments for severe sleep conditions, according to investment bank Oppenheimer.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.